5T4-derived peptide–MHC complex

The 5T4-derived peptide–MHC complex is formed when peptides originating from the 5T4 (trophoblast glycoprotein) antigen are processed and loaded onto MHC class I or MHC class II molecules within a cell. MHC class I complexes present these peptides to cytotoxic CD8+ T cells, typically leading to direct killing of cells displaying abnormal or tumor-associated antigens. MHC class II complexes present peptides to CD4+ helper T cells, supporting orchestration of broader immune responses[1][4][5][6]. These complexes play a key role as therapeutic targets in cancer immunotherapy by enabling immune recognition of tumors expressing 5T4. MHC class I molecules present peptides mostly derived from endogenous (intracellular) proteins and are recognized by CD8+ T cells, resulting in their activation and target cell lysis[4][6]. MHC class II molecules present peptides from exogenous sources (e.g., proteins taken up from the extracellular space), and are primarily recognized by CD4+ T cells, leading to immune modulation and activation of effector cells[1][2][6]. Targeting tumor-associated antigens such as 5T4–derived peptides in the context of MHC has been investigated for cancer vaccines and adoptive cell therapies. The specificity of the response depends both on the peptide sequence and the polymorphic MHC allele presenting the peptide[3][6]. "5T4-derived peptides presented by MHC class I/II molecules" is not the name of a single gene or protein but rather describes a class of peptide–MHC complexes. However, these complexes are considered actionable therapeutic targets, especially in cancer vaccine and T-cell engineering strategies, and thus meet the criteria for a "target" in biomedical research. When referencing "5T4-derived peptide–MHC complex," the canonical abbreviation is not in widespread use, so null is appropriate. Drug interactions pertain to immunotherapeutic strategies (e.g., vaccines, TCR-engineered T cells) that specifically recognize these complexes, rather than small molecules or standard drugs. If you are seeking information about the underlying gene, see "Trophoblast glycoprotein" (abbreviated "5T4"); when asking about the immunological target, the above conventions apply.

Other names

5T4 antigen-derived peptide–MHC complex5T4 peptide–MHCTrophoblast glycoprotein-derived peptide–MHC complex

Presentation of specific peptides by MHC I induces cytotoxic CD8+ T-cell responses; presentation by MHC II induces CD4+ T-cell activation and helper responses.